Mergers and Acquisitions

PCI's acquisition of Biotech Services International expands the packaging services provider's presence in Europe.

DPT Laboratories acquired Media Pharmaceuticals' Lakewood, New Jersey facilities, providing space for aseptic processing suites and filling equipment.

PSC Investments announces the acquisition of a high potency, sterile fill/finish pharmaceutical manufacturing facility.

Genia's DNA-sequencing platform will strengthen Roche's pipeline.

Provence Technologies? strengthens its expertise in therapeutic chemistry with acquisition of Synprosis.

Aastrom acquires Sanofi's CTRM business unit for $6.5 million.

Repligen acquired Refine Technology and its Alternating Tangential Flow system for continuous bioprocessing.

KBI Biopharma acquires Merck's microbial process development and manufacturing operations in Colorado.

Shire expands rare disease portfolio with acquisition of Lumena Pharmaceuticals.

Tigermed acquires Frontage Laboratories for $50.25 million.

BMS acquisition of iPierian advances BMS' pursuit of therapeutics for genetically defined diseases.

Sartorius Stedim Biotech's acquisition of AllPure Technologies will extends its portfolio for single-use bioprocessing.

Aastrom Biosciences will acquire Sanofi's CTRM business for $6.5 million.

Eurofins acquires DDS business of Merck KGaA in order to expand discovery solutions and bioanalytical services.

GE acquires Thermo Fisher-s HyClone cell culture media and sera products, gene modulation technologies, and magnetic beads businesses.

MedImmune expands its antibody-drug conjugate capability through acquisition and collaboration.

Malvern Instruments has acquired NanoSight, the UK-based nanoparticle characterization company.

The move doubles the CRO’s capacity in Europe.

GSK expands its vaccines platform technology expertise by acquiring Okairos, a Swiss-based company.

Unique technology expands Entegris? fluid-sensing and control offering.

Mylan announced that it has signed an agreement to acquire the generic injectables unit Agila Specialties from Strides Arcolab for $1.6 billion in cash.

Biogen Idec has agreed to acquire full Tysabri rights from Elan, and will use its existing cash reserves to make a payment of $3.25 billion to Elan upon the closing of the transaction and make future contingent payments to Elan.

Shire has signed an agreement to acquire Lotus Tissue Repair, Inc., a biotechnology company developing the first and only protein replacement therapy for the orphan disease, dystrophic epidermolysis bullosa (DEB).

Bayer expands animal health business with acquisition from Teva.

On Nov. 21, 2011, Gilead Sciences agreed to acquire Pharmasset for $137 per share in cash, or a total of approximately $11 billion. Pharmasset’s board of directors unanimously approved the transaction, which is expected to close during the first quarter of 2012. Gilead will finance the transaction with cash, bank debt, and senior unsecured notes.